Xuanyong Lu
President & CSO
Ph.D. from Goettingen University, Germany and B.S. from Nanjing University, China.
Formerly a Professor at Drexel University’s Institute for Biotechnology and Virology and the inventor of the technologies that form the basis of Seravue®, Xuanyong brings the key technical expertise to lead ImCare Biotech. His previous research focused on the development of long-term Hepatitis and the development of liver cancer. Xuanyong holds a Bachelor’s of Science from Nanjing University, China and a Ph.D. from Goettingen University, Germany. Xuanyong has more than 50 publications in prestigious academic journals and is the inventor of 5 patented technologies.
Aaron Yefei Lu
Chief Executive Officer
M.B.A from London Business School and B.A. from Stanford University.
Formerly a management consultant at McKinsey & Company, Aaron brings a strong background in general business management and operational efficiency. His expertise comes from working at numerous Fortune 500 companies including those in med-tech and pharma. In the past five years, Aaron has worked in public and private equity where he was involved with med-tech investments in the diagnostic assay market. These experiences are being applied to help ImCare transition smoothly from a small R&D startup to a successful commercial entity. Aaron holds an M.B.A from London Business School, United Kingdom and a Bachelor of Arts in Economics with Honors from Stanford University, USA.
Bobby Biswal
VP of Engineering
As ImCare Biotech’s VP of Engineering, Bobby is leading the development of the company’s software and AI programs. His strong background in data science, machine learning and software management is enabling ImCare Biotech to develop high performing diagnostic models and accompanying software products.
Prior to joining ImCare Biotech, Bobby held engineering and product leadership roles at Cisco, where he led escalation engineering for security products and at Ooma, where he developed new telephony software platforms that grew to $130M in annual recurring revenue. In his recent experience at Amazon Alexa AI, he launched a new unified model building platform to manage the full lifecycle of large-scale language models, including their authoring, evaluation and release. The diverse software platforms Bobby has built in his career are being used by millions of users around the world.
Bobby holds a M.S. in Engineering Management from the University of Southern California and a B.S. in Electrical Engineering from Stanford University.
Felix Lu
VP of Product and Operations
B.S. in Molecular Biophysics and Biochemistry from Yale University.
Felix is a skilled product manager with experience bringing class II medical devices from concept to commercialization. Most recently, Felix worked as a Sr. Product Manager at Caldera Medical, a company focused on innovative surgical products in the field of women’s pelvic health. There, he was responsible for identifying and driving the development of new products across core and adjacent therapeutic areas. Working specifically within small biotech and medtech companies, he brings knowledge across a range of functional areas, including operations, R&D, marketing, regulatory and clinical. By combining technical and business development expertise, Felix is well-suited to lead and organize the team’s ongoing efforts across multiple avenues.
Kshama Mehta, Ph.D.
Director of Clinical Operations
Kshama Mehta, Ph.D., is the Director of Clinical Operations at ImCare Biotech, bringing over a decade of multidisciplinary experience in clinical trial operations and regulatory management. She has a proven track record of overseeing phase 1-4 clinical trials in adult and pediatric populations in various therapeutic areas including nephrology, rare diseases, and oncology. Kshama is adept at managing large project teams and collaborating with diverse stakeholders, demonstrating expertise in project management, strategic planning, and operations. Her contributions to ImCare Biotech include establishing clinical trial infrastructure, developing trial SOPs, and ensuring successful global rollout of liver cancer diagnostic tests, reflecting her commitment to advancing clinical research and operational excellence.